<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AZITHROMYCIN</span><br/>(a-zi-thro-mye'sin)<br/><span class="topboxtradename">Zithromax, </span><span class="topboxtradename">Zmax<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">macrolide antibiotic</span><br/><b>Prototype: </b>Erythromycin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 600 mg tablets; 100 mg/5 mL, 200 mg/5 mL, 1 g/packet oral suspension; 500 mg injection; 
         				<b>Zmax</b> extended release: 176 mg/5 mL oral suspension
      </p>
<h1><a name="action">Actions</a></h1>
<p>A macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible organisms and consequently inhibits
         protein synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective for treatment of mild to moderate infections caused by pyogenic streptococci, <i>Streptococcus pneumoniae, Haemophilus influenzae,</i> and <i>Staphylococcus aureus.</i>
</p>
<h1><a name="uses">Uses</a></h1>
<p>Pneumonia, lower respiratory tract infections, pharyngitis/tonsillitis, gonorrhea, nongonococcal urethritis, skin and skin
         structure infections due to susceptible organisms, otitis media, <i>Mycobacterium aviumintracellulare</i> complex infections, acute bacterial sinusitis. <b>Zmax:</b> acute bacterial sinusitis and community acquired pneumonia.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Bronchitis, <i>Helicobacter pylori</i> gastritis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to azithromycin, erythromycin, or any of the macrolide antibiotics.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults or debilitated persons, hepatic or renal impairment; GI disease; ventricular arrhythmias, QT prolongation; UV
         exposure; pregnancy (category B), and lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Bacterial Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg on day 1, then 250 mg q24h for 4 more d <span class="rdroute">IV</span> 500 mg q.d. for at least 2 d, administer 1 mg/mL over 3 h or 2 mg/mL over 1 h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>6 mo,</i> 10 mg/kg on day 1, then 5 mg/kg for 4 more d (max: 250 mg/d)<br/><br/><span class="indicationtitle">Acute Bacterial Sinusitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg once daily <small>x</small> 3 d. <b>Zmax:</b> single one-time dose of 2 g.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i><img src="../images/special/greaterorequal.gif"/>6 mo</i>, 10 mg/kg once daily <small>x</small> 3 d<br/><br/><span class="indicationtitle">Otitis Media</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;6 mo,</i> 30 mg/kg as a single dose or 10 mg/kg once daily (not to exceed 500 mg/d) for 3 d or 10 mg/kg as a single dose on day 1 followed
               by 5 mg/kg/d on days 25<br/><br/><span class="indicationtitle">Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g as a single dose<br/><br/><span class="indicationtitle">Chancroid</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 g as a single dose<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 20 mg/kg as single dose (max: 1 g)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give capsule at least 1 h before or 2 h after a meal. Tablets may be taken without regard to food.</li>
<li>Do not give within 2 h of an aluminum or magnesium-containing antacid.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Intermittent:</span> Reconstitute 500-mg vial with 4.8 mL of sterile water for injection and shake until dissolved. Final concentration is 100
                  mg/mL. Solution must be further diluted to 1.0 or 2.0 mg/mL by adding 5 mL of the 100-mg/mL solution to 500 mL or 250 mL,
                  respectively, of D5W, D5/NS, 0.45NS, or other compatible solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Administer diluted solution over at least 60 min. Do not give a bolus dose.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Amikacin,</b>
<b>aztreonam,</b>
<b>cefotaxime,</b>
<b>ceftazidime,</b>
<b>ceftriaxone,</b>
<b>cefuroxime,</b>
<b>ciprofloxacin,</b>
<b>clindamycin,</b>
<b>famotidine,</b>
<b>fentanyl,</b>
<b>furosemide,</b>
<b>gentamicin,</b>
<b>imipenem/cilastatin,</b>
<b>ketorolac,</b>
<b>levofloxacin,</b>
<b>morphine,</b>
<b>piperacillin/tazobactam,</b>
<b>ticarcillin/clavulanate,</b>
<b>tobramycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store drug when diluted as directed for 24 h at or below 30° C (86° F) or for 7 d under 5° C (41° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, abdominal pain; <span class="speceff-life">hepatotoxicity</span>, mild elevations in liver function tests. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Liver function tests: reversible, asymptomatic elevations in <span class="alt">liver enzymes (AST, ALT, gamma glutamyl transferase, alkaline phosphatase)</span> have been reported in some patients treated with azithromycin.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antacids</span> may decrease peak level of azithromycin; may increase toxicity of <b>dihydroergotamine,</b>
<b>ergotamine.</b>
<span class="typehead">Food:</span> Food will decrease the amount of azithromycin absorbed by 50%. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 37% of dose reaches the systemic circulation. <span class="typehead">Onset:</span> 48 h. <span class="typehead">Peak:</span> 2.54 h. <span class="typehead">Distribution:</span> Extensively distributed to most tissues including sputum, blister, and vaginal secretions; tissue concentrations are often
      higher than serum concentrations. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 512% of dose is excreted in urine. <span class="typehead">Half-Life:</span> 6070 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report loose stools or diarrhea, since pseudomembranous colitis (see Appendix F) must be ruled out.</li>
<li>Monitor PT and INR closely with concurrent warfarin use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Direct sunlight (UV) exposure should be minimized during therapy with drug.</li>
<li>Take aluminum or magnesium antacids 2 h before or after drug.</li>
<li>Report onset of loose stools or diarrhea.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>